VentureOne reported this morning that venture capital investment was modestly improved — although the tech sector wasn’t the primary beneficiary of the improvement.
The healthcare sector was the major driver of the increase in the overall
amount invested, with biopharmaceuticals and medical devices performing
particularly well due to growth in deal flow. Investment in biopharmaceutical
companies nearly doubled from the previous quarter, to $745 million, the
highest level since last year at this time. All areas within
biopharmaceuticals thrived, with the exception of drug delivery. The principal
contributors to the success of the medical devices segment were implantable
therapeutic devices companies.